FROM INNOVATION TO INTERVENTION
RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is developing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established 21 CFR 211 compliant contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, in addition to small animal Molecular Imaging Center for the pre-clinical evaluation of new targets in vitro and in vivo.
• Pre-clinical screening
• Cellular binding
• In vitro studies
• Selection of lead candidates
• Micro PET imaging center
• Biodistribution
• PK
• Tox Studies
• Formulation of kits
• Clinical doses
• Support Phase I-III studies
RadioMedix offers a multitude of services. Our bench to bedside capabilities include drug candidate selection, optimization of the drug formulation, evaluation of in vitro and in vivo studies in relevant disease models and a multitude of other preclinical services. When it comes to clinical trials, our team of scientists are prepared to meet your manufacturing needs including radiochemistry solutions, analytical method developments, process validation, manufacturing and testing under GMP guidelines.
Driven by innovation, we have built a full-service, self-sufficient, cutting-edge facility in Houston Texas. Conceived from best-practices, the Spica center is purposefully designed to lead the industry in time-to-market, quality, and volume. Our state-of-the-art facility is in full compliance with 21 CFR 211. Partnering with RadioMedix guarantees a meticulous manufacturing process, a reliable supplier, and safety-committed experts with a wealth of experience. Whatever your radiopharmaceutical needs, RadioMedix is open for business.
At Radiomedix, We utilize targeted radionuclide treatment to diagnose and treat patients. This theranostic approach allows for diagnosing patient maladies with precision and control of disease.
